BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9616968)

  • 1. Clinical and pathological prognostic factors in canine mammary tumors.
    Pérez Alenza MD; Peña L; Nieto AI; Castaño M
    Ann Ist Super Sanita; 1997; 33(4):581-5. PubMed ID: 9616968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
    Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
    J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: relationship with clinical and histological characteristics.
    Peña L; De Andrés PJ; Clemente M; Cuesta P; Pérez-Alenza MD
    Vet Pathol; 2013 Jan; 50(1):94-105. PubMed ID: 22688585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative treatment outcome in canine mammary tumors. Multivariate analysis of the prognostic value of pre- and postoperatively available information.
    Betz D; Schoenrock D; Mischke R; Baumgärtner W; Nolte I
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2012; 40(4):235-42. PubMed ID: 22911254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms.
    Sorenmo KU; Rasotto R; Zappulli V; Goldschmidt MH
    Vet Pathol; 2011 Jan; 48(1):85-97. PubMed ID: 21147765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival.
    Gama A; Paredes J; Gärtner F; Alves A; Schmitt F
    Vet J; 2008 Jul; 177(1):45-53. PubMed ID: 17631398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
    Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A
    Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
    Gama A; Alves A; Schmitt F
    Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of regional lymph node status in canine mammary carcinomas.
    Szczubiał M; Łopuszynski W
    Vet Comp Oncol; 2011 Dec; 9(4):296-303. PubMed ID: 22077411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumours.
    Queiroga FL; Pires I; Lobo L; Lopes CS
    Res Vet Sci; 2010 Jun; 88(3):441-5. PubMed ID: 19939424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study.
    De Matos AJ; Lopes CC; Faustino AM; Carvalheira JG; Dos Santos MS; Rutteman GR; Gärtner Mde F
    Anticancer Res; 2006; 26(3A):1821-6. PubMed ID: 16827113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
    Queiroga FL; Perez-Alenza MD; Silvan G; Peña L; Lopes C; Illera JC
    Anticancer Res; 2005; 25(6B):4269-75. PubMed ID: 16309227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic status of p53 gene mutation in canine mammary carcinoma.
    Wakui S; Muto T; Yokoo K; Yokoo R; Takahashi H; Masaoka T; Hano H; Furusato M
    Anticancer Res; 2001; 21(1B):611-6. PubMed ID: 11299814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog.
    de Las Mulas JM; Millán Y; Dios R
    Vet Pathol; 2005 Mar; 42(2):200-12. PubMed ID: 15753474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study.
    Santos A; Lopes C; Frias C; Amorim I; Vicente C; Gärtner F; Matos Ad
    Vet J; 2011 Dec; 190(3):396-402. PubMed ID: 21269852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced PTEN protein expression and its prognostic implications in canine and feline mammary tumors.
    Ressel L; Millanta F; Caleri E; Innocenti VM; Poli A
    Vet Pathol; 2009 Sep; 46(5):860-8. PubMed ID: 19429983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical staining of metallothionein in canine mammary tumors: better survival with higher expression.
    Cardoso SV; Caliari MV; de Aguiar MC; Cassali GD
    Oncol Rep; 2004 Dec; 12(6):1317-21. PubMed ID: 15547757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for dogs with mammary inflammatory carcinoma: 43 cases (2003-2008).
    Marconato L; Romanelli G; Stefanello D; Giacoboni C; Bonfanti U; Bettini G; Finotello R; Verganti S; Valenti P; Ciaramella L; Zini E
    J Am Vet Med Assoc; 2009 Oct; 235(8):967-72. PubMed ID: 19827983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases.
    Hellmén E; Bergström R; Holmberg L; Spångberg IB; Hansson K; Lindgren A
    Vet Pathol; 1993 Jan; 30(1):20-7. PubMed ID: 8442324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours.
    Ferreira E; Bertagnolli AC; Cavalcanti MF; Schmitt FC; Cassali GD
    Vet Comp Oncol; 2009 Dec; 7(4):230-5. PubMed ID: 19891693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.